Poor
Not Aligned
Patient Risk:
Medium
Summary
Multiple extracted claims are not supported by the provided FDA label sections, including several that add specific dosing/regimen and clinical-effect assertions not present in the supplied label text.
Category Scores
Accurate Statements
Cytotec is the brand name for misoprostol.
INDICATIONS AND USAGE (Cytotec (misoprostol))
For prevention of NSAID-related gastric ulcers, misoprostol dosing is taken multiple times per day with food.
DOSAGE AND ADMINISTRATION (200 mcg four times daily with food; last dose at bedtime)
Cytotec dosing comes from the product label for the approved indication.
DOSAGE AND ADMINISTRATION (recommended adult oral dose for reducing risk of NSAID-induced gastric ulcers)
In OB settings, uterine contractions can become too strong, increasing risk.
LABOR AND DELIVERY (uterine tachysystole → uterine tetany with marked impairment of uteroplacental blood flow; uterine rupture)
Unsupported Statements
Treatment dosing for an existing gastric ulcer is a different regimen than prevention.
Provided label sections include a dose regimen for reducing the risk of NSAID-induced gastric ulcers (prevention) but do not describe a labeled treatment regimen for an existing gastric ulcer.
Ulcer healing depends on sustained dosing over the treatment period for existing ulcer treatment.
No provided label text states ulcer healing timing/dependence on a treatment-period regimen for existing ulcers.
In obstetrics, misoprostol dosing is highly protocol-dependent.
Provided label text does not use or support the characterization 'highly protocol-dependent' for obstetric dosing.
In obstetrics, misoprostol dosing depends on gestational age and route (oral vs vaginal vs buccal) and whether the cervix is favorable.
Gestational age risk is supported, but route-specific (oral vs vaginal vs buccal) dosing and 'cervix favorable' dependence are not supported by the provided label sections.
Misoprostol dosing differs by whether the product is being used for an off-label indication.
The provided label sections discuss 'outside of its approved indication' use but do not provide a labeled dosing regimen that varies specifically by off-label indication.
Misoprostol can cause diarrhea, abdominal cramps, and nausea.
Provided label text clearly reports diarrhea and abdominal pain; nausea is not clearly supported in the cited adverse-reaction content.
Diarrhea, abdominal cramps, and nausea with misoprostol are dose-related.
The label states diarrhea is dose related; it does not clearly state abdominal pain or nausea are dose-related.
Misoprostol can cause fever and chills.
Provided label text mentions high fevers in postpartum hemorrhage contexts but does not support chills.
Misoprostol is not appropriate in certain pregnancy scenarios without a clinician-led protocol.
The label supports restrictions and the need for trained obstetrical monitoring, but the specific standard 'without a clinician-led protocol' is not supported by the provided text.
Cytotec dosing for off-label uses comes from clinical protocols.
The provided label sections do not state that dosing for off-label uses comes from clinical protocols.
Contradictions
Important Omissions
Boxed warning details and exact contraindication language beyond the referenced pregnancy prohibition (e.g., explicit instruction not to use in pregnancy to reduce ulcer risk and allergy contraindication) were not specifically evaluated by the claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several claims add or imply dosing regimens for uses or clinical scenarios not described in the provided label sections (e.g., existing gastric ulcer treatment, route/cervix-favorability for obstetric contexts, and off-label dosing source), which could mislead dosing decisions if acted upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple extracted claims include dosing/regimen or clinical-effect specificity not supported by the provided FDA label text (especially existing ulcer treatment, obstetric route/cervix favorability, and off-label dosing source).
Suggested Improvement
Limit statements strictly to the provided label language (NSAID-induced ulcer prevention regimen; pregnancy restriction; reported adverse events explicitly mentioned such as diarrhea and abdominal pain; and uterine tachysystole/rupture risks) and avoid asserting missing regimen details or specific qualifiers (e.g., 'highly protocol-dependent', 'clinician-led protocol', route/cervix-favorability, nausea/chills dose-relatedness).